Sculptor Capital’s ImmunityBio IBRX Stock Holding History

Sculptor Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$693K	Sell	79,200 -10,000	-11%	-$75.7K	0.01%	286
2026 Q1	$684K	Sell	89,200 -529,800	-86%	-$3.63M	0.01%	259
2025 Q4	$1.23M	Hold	619,000	–	–	0.01%	267
2025 Q3	$1.52M	Buy	619,000 +310,400	+101%	+$799K	0.02%	239
2025 Q2	$815K	Buy	+308,600	New	+$830K	0.01%	256
2025 Q1	–	Sell	-270,800	Closed	-$821K	–	350
2024 Q4	$693K	Buy	270,800 +53,000	+24%	+$221K	0.01%	229
2024 Q3	$810K	Buy	217,800 +95,300	+78%	+$441K	0.01%	205
2024 Q2	$774K	Sell	122,500 -143,700	-54%	-$947K	0.01%	173
2024 Q1	$1.43M	Buy	266,200 +186,700	+235%	+$845K	0.03%	148
2023 Q4	$399K	Sell	79,500 -51,800	-39%	-$163K	0.01%	209
2023 Q3	$222K	Hold	131,300	–	–	﹤0.01%	233
2023 Q2	$365K	Buy	131,300 +82,100	+167%	+$232K	0.01%	222
2023 Q1	$89.5K	Hold	49,200	–	–	﹤0.01%	319
2022 Q4	$249K	Hold	49,200	–	–	﹤0.01%	478
2022 Q3	$245K	Buy	+49,200	New	+$224K	﹤0.01%	653
2022 Q1	–	Sell	-153,300	Closed	-$932K	–	1264
2021 Q4	$932K	Sell	153,300 -4,800	-3%	-$36.1K	0.01%	688
2021 Q3	$1.54M	Hold	158,100	–	–	0.01%	516
2021 Q2	$2.26M	Hold	158,100	–	–	0.02%	487
2021 Q1	$3.75M	Buy	158,100 +151,300	+2,225%	+$3.92M	0.03%	327
2020 Q4	$91K	Buy	+6,800	New	+$65.4K	﹤0.01%	469

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sculptor Capital's IBRX Position: Q2 2026 in Review

Sculptor Capital reduced its ImmunityBio (IBRX) stake by 11% in Q2 2026, selling an estimated $75.7K and leaving 79,200 shares worth $693K. The position accounts for 0.01% of the portfolio, ranked #286.

Sculptor Capital first reported a position in IBRX in Q4 2020 and has held it in 20 quarters since. The position peaked at $3.75M in Q1 2021. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Sculptor Capital held 79,200 shares of ImmunityBio worth $693K as of Q2 2026.
Sculptor Capital sold 10,000 ImmunityBio shares in Q2 2026, an estimated $75.7K.
ImmunityBio made up 0.01% of Sculptor Capital's portfolio in Q2 2026, its #286 holding.
Sculptor Capital first reported a position in ImmunityBio in Q4 2020 and has held it in 20 quarters since.
Sculptor Capital's ImmunityBio position peaked at $3.75M in Q1 2021.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Sculptor Capital's 13F filing for Q2 2026, filed 14 Aug 2026.